Joseph Wolk - Johnson Johnson Chief Financial Officer, Executive Vice President

JNJ -- USA Stock  

Fiscal Quarter End: December 31, 2019  

  President
Mr. Joseph J. Wolk is Chief Financial Officer, Executive Vice President of the Company. He was previously Vice President, Group Finance for the Pharmaceuticals Group of Johnson Johnson, where he provided finance leadership, supporting Worldwide Chairman, Pharmaceuticals Joaquin Duato, and Chief Scientific OfficerPaul Stoffels, as a member of the Pharmaceuticals Group Operating Committee. Prior to that role, he held other finance leadership positions at Johnson Johnson as Vice President of Finance for the Medical Devices Global Supply Chain, and as Chief Financial Officer of the North America Pharmaceuticals Group, responsible for Centocor Ortho Biotech Inc. as well as U.S. Pricing Strategy and Compliance. Wolk joined Johnson Johnson in 1998 as a Finance Manager in the OrthoMcNeil Pharmaceutical organization. Prior to joining Johnson Johnson, Wolk held multiple positions of increasing responsibility at Ametek, Inc. He holds a BS degree in Finance from St. Joseph University, where he currently serves on the Haub School of Business Board of Visitors, and he also holds a Juris Doctor degree from Temple University School of Law and is a Certified Public Accountant.
Age: 51  President Since 2018      
732-524-0400  http://www.jnj.com

Management Efficiency

The company has Return on Asset of 0.12 % which means that on every $100 spent on asset it made $0.12 of profit. This is way below average. In the same way, it shows return on shareholders equity (ROE) of 0.22 % implying that it generated $0.22 on every 100 dollars invested.
The company has 30.43 B in debt with debt to equity (D/E) ratio of 50.0 . This implies that the company may be unable to create cash to meet all of its financial commitments. Johnson Johnson has Current Ratio of 1.3 demonstrating that it may not be capable to disburse its financial commitments when the payables are due.

Entity Summary

Johnson Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. The company was incorporated in 1887 and is based in New Brunswick, New Jersey. Johnson Johnson operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange. It employs 135100 people.Johnson Johnson (JNJ) is traded on BATS Exchange in USA. It is located in One Johnson & Johnson Plaza and employs 135,100 people. Johnson Johnson is listed under Pharmaceutical Products category by Fama And French industry classification.

Johnson Johnson Leadership Team

A Washington, Independent Director
Jennifer Doudna, Independent Director
Alex Gorsky, Chairman, CEO, Chairman of Executive Committee and Chairman of Fin. Committee
William Perez, Independent Director
Michael Sneed, Executive Vice President - Global Corporate Affairs and Chief Communication Officer
Marillyn Hewson, Independent Director
Jorge Mesquita, Executive Vice President Worldwide Chairman - Consumer
Mary Coleman, Independent Director
Michael Ullmann, VP, General Counsel and Member of Executive Committee
Joaquin Duato, Executive Vice President Worldwide Chairman - Pharmaceuticals
Kathy Wengel, Executive Vice President Chief Global Supply Chain Officer
Jennifer Taubert, Executive Vice President - Worldwide Chairman, Pharmaceuticals
Mary Beckerle, Independent Director
Sandra Peterson, Group Worldwide Chairman and Member of Executive Committee
Scott Davis, Director
Louise Mehrotra, Vice President Investor Relations
Ashley McEvoy, Executive Vice President - Worldwide Chairman, Medical Devices
Ronald Williams, Independent Director
Kathryn Wengel, Executive Vice President Chief Global Supply Chain Officer
D Davis, Independent Director
Anne Mulcahy, Lead Independent Director
Joseph Wolk, Chief Financial Officer, Executive Vice President
Thibaut Mongon, Executive Vice President Worldwide Chairman, Consumer
Ian Davis, Independent Director
Paulus Stoffels, Worldwide Chairman of Pharmaceuticals, Chief Scientific Officer and Member of Executive Committee
Mark McClellan, Independent Director
Charles Prince, Independent Director
Eugene Washington, Independent Director
Dominic Caruso, CFO, VP of Fin. and Member of Executive Committee
Peter Fasolo, Chief Human Resource Officer, Executive Vice President
Susan Lindquist, Independent Director

Stock Performance Indicators

Did you try this?

Run Portfolio Comparator Now

   

Portfolio Comparator

Compare the composition, asset allocations and performance of any two portfolios in your account
All  Next Launch Module

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please also check Risk vs Return Analysis. Please also try Idea Breakdown module to analyze constituents of all macroaxis ideas. macroaxis investment ideas are predefined, sector-focused investing themes.
Search macroaxis.com